|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM15300620X |
| 003 |
DE-627 |
| 005 |
20231223063143.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0510.xml
|
| 035 |
|
|
|a (DE-627)NLM15300620X
|
| 035 |
|
|
|a (NLM)15639648
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Goldberg, Anna Carla
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Exogenous leptin restores in vitro T cell proliferation and cytokine synthesis in patients with common variable immunodeficiency syndrome
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.03.2005
|
| 500 |
|
|
|a Date Revised 15.11.2006
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Common variable immunodeficiency (CVID) is a primary immunodeficiency characterized by hypogammaglobulinemia. Leptin has been implicated as an antiapoptotic compound as well as a stimulant of the immune response. Leptin administration is capable of reversing the immune deficiency that occurs upon starvation. We investigated a possible role for leptin in CVID; a condition associated with lowered plasma leptin levels. Thirty-eight patients were studied. Addition of leptin to the tissue culture media of PBMC from CVID patients increased the proliferative response of lymphocytes to mitogens and decreased activation-induced apoptosis of these cells. IL-2 and specially IL-4 production also increased significantly upon addition of leptin to the PBMC cultures. Our results suggest that leptin may be involved in some of the cellular defects observed in CVID and indicate a novel therapeutic strategy to improve immune function in these patients
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Interleukin-2
|2 NLM
|
| 650 |
|
7 |
|a Leptin
|2 NLM
|
| 650 |
|
7 |
|a Interleukin-4
|2 NLM
|
| 650 |
|
7 |
|a 207137-56-2
|2 NLM
|
| 700 |
1 |
|
|a Eliaschewitz, Freddy Goldberg
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Montor, Wagner Ricardo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Baracho, Gisele Vanessa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Errante, Paolo Ruggero
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Callero, Mariana Alejandra
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Cardoso, Maria Regina Alves
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Braga, Patricia Emilia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kalil, Jorge
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sogayar, Mari Cleide
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rizzo, Luiz Vicente
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 114(2005), 2 vom: 10. Feb., Seite 147-53
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:114
|g year:2005
|g number:2
|g day:10
|g month:02
|g pages:147-53
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 114
|j 2005
|e 2
|b 10
|c 02
|h 147-53
|